SCHEMBL17154396

SCHEMBL17154396

O=C(CCl)Nc1ccc(Nc2c3ccccc3nc3ccccc23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.68
MITF O75030 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
KDM4E B2RXH2 1/20 0.68
LMNA P02545 1/20 0.68
POLB P06746 1/20 0.68
MAPT P10636 1/20 0.68
RAD52 P43351 1/20 0.68
RECQL P46063 1/20 0.68
KMT2A Q03164 1/20 0.68
NPSR1 Q6W5P4 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
HDAC3 O15379 3/20 0.61
HDAC4 P56524 3/20 0.61
HDAC1 Q13547 3/20 0.61
HDAC7 Q8WUI4 3/20 0.61
HDAC2 Q92769 3/20 0.61
HDAC8 Q9BY41 3/20 0.61
HDAC6 Q9UBN7 3/20 0.61
HDAC9 Q9UKV0 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154367 0.87 KDM1A (0.69) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL17154414 0.85 KDM4E (0.61) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL17154400 0.81 KDM1A (1.00) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL11655190 0.80 ALDH1A1 (0.73) MITFSMN1; SMN2KDM4ELMNAPOLB
SCHEMBL17154429 0.78 KDM1A (0.64) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL17154369 0.77 KDM4E (0.53) SMN1; SMN2KDM4EPOLBMAPTKMT2A
SCHEMBL44662 0.76 HTT (0.78) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL902770 0.76 KDM1A (1.00) KDM1AMITFSMN1; SMN2KDM4ELMNA
SCHEMBL15673265 0.75 KDM1A (0.75) KDM1APOLBRAD52KMT2AATM
SCHEMBL4939506 0.75 KDM1A (0.75) KDM1AMITFSMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KDM1A 702/4885MITF 1784/4885SMN1; SMN2 4168/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KDM1A 650/4885MITF 1859/4885SMN1; SMN2 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.